RESULTS REVIEW 1QFY19 27 JUL 2018
Colgate-Palmolive (India) NEUTRAL
HDFC securities Institutional Research is also available on Bloomberg HSLB <GO>& Thomson Reuters
Seeking aggression Colgate registered 6.6/4% revenue/volume growth (exp. 11/6%). Despite favorable base (-5% in 1QFY18), good traction for Swarna Vedshakti and improving consumption dynamics, volume growth remained tepid. Soft input inflation and cost control initiatives (flat Ad spend) drove EBITDA/PAT by 27/21% (exp. 18/18%). However, we are not encouraged by margin expansion, since we wanted to see an aggressive approach from the market leader in a challenging period. Muted ad spend and gross margin expansion in the scenario of continued market share fall and improving consumption dynamics, reflects weak management strategy.
Market share of toothpaste continued to decline (190bps YoY fall to 52.4%) along with toothbrush (40bps YoY fall to 44.6%). Dabur and Patanjali continue to gain share. Toothpaste industry continues to chug along at 5-6% volume growth. Rural is growing at slower than historical rates (150bps faster than urban vs. historical gap of 300-400bps). We believe with recovery in rural consumption, volume growth can accelerate to 6-7% for the category. Naturals segment (25% industry mix) continues to outperform. Colgate amidst Swarna Vedshakti’s (~2% market share) pan-India launch cut its price by 15%.
Management is committed to driving Swarna’s geographic reach with wider SKUs. We are yet to see signs of recovery and believe market share pressure will persist in the short-term. We model 11% revenue CAGR during FY18-21E, which factors in pass through of higher inflation and recovery in rural demand. Owing to stiff competition, we expect Colgate to continue to spend abundantly on marketing (~13%). We value Colgate based on P/E of 35x on Jun-20 EPS to arrive at a TP of Rs 1,185 (Rs 1,219). Highlights of the quarter 27% EBITDA growth: GM expanded by 255bps to
65.9% owing to soft commodity inflation. A&P growth was flat YoY (-8% in 1QFY18). Employee/other expenses increased by 3/3%. EBITDA margin expanded by 436bps to 27% (exp. of 24%).
APAT grew by 21%: Depreciation/other income declined/taxes grew by 6/-26/58% YoY resulting in APAT (excluding profit of Rs 341mn from sale of plant) growing by 21% to Rs 1.65bn vs. (exp. of Rs 1.61bn).
Near-term outlook: We prefer other mid-cap FMCG stocks like (Emami, Marico and Dabur) which provide stronger earnings visibility.
Financial Summary (Rs mn) 1QFY19 1QFY18 YoY (%) 4QFY18 QoQ (%) FY17 FY18 FY19E FY20E FY21E Net Sales 10,413 9,781 6.5 10,917 (4.6) 39,818 41,880 45,628 50,806 56,508 EBITDA 2,816 2,218 26.9 3,075 (8.4) 9,444 11,124 12,588 14,580 16,617 APAT 1,656 1,364 21.4 1,791 (7.5) 5,774 6,637 7,825 8,931 10,285 Diluted EPS (Rs) 6.1 5.0 21.4 6.6 (7.5) 21.2 24.4 28.7 32.8 37.8 P/E (x) 51.1 44.5 37.7 33.0 28.7 EV / EBITDA (x) 30.9 26.1 23.1 19.7 17.0 Core RoCE (%) 64.5 64.4 69.6 81.9 96.1 Source: Company, HDFC sec Inst Research
INDUSTRY FMCG
CMP (as on 26 Jul 2018) Rs 1,085
Target Price Rs 1,185
Nifty 11,167 Sensex 36,985
KEY STOCK DATA Bloomberg CLGT IN
No. of Shares (mn) 272 MCap (Rs bn)/(US$ mn) 295/4,298 6 m avg traded value (Rs mn) 461
STOCK PERFORMANCE (%) 52 Week high / low Rs 1,274/1,006 3M 6M 12M Absolute (%) (0.8) (4.9) 2.7 Relative (%) (7.3) (7.5) (11.5)
SHAREHOLDING PATTERN (%) Promoters 51.00 FIs & Local MFs 15.14 FPIs 11.45 Public & Others 22.41 Source : BSE
Naveen Trivedi [email protected] +91-22-6171-7324 Siddhant Chhabria [email protected] +91-22-6171-7336
COLGATE-PALMOLIVE : RESULTS REVIEW 1QFY19
Page | 2
Quarterly Financials Particulars (Rs mn) 1QFY19 1QFY18 YoY (%) 4QFY18 QoQ (%) FY18 FY17 YoY (%) Net Revenue 10,413 9,781 6.5 10,917 (4.6) 41,880 39,818 5.2 Material Expenses 3,550 3,584 (1.0) 3,750 (5.3) 14,901 14,763 0.9 Employee Expenses 749 727 3.0 758 (1.2) 3,059 2,885 6.0 ASP Expenses 1,435 1,434 0.1 1,436 (0.0) 5,268 5,117 3.0 Other Operating Expenses 1,863 1,818 2.5 1,898 (1.8) 7,528 7,617 (1.2) EBITDA 2,816 2,218 26.9 3,075 (8.4) 11,124 9,436 17.9 Depreciation 394 373 5.6 405 (2.7) 1,565 1,332 17.5 EBIT 2,422 1,845 31.3 2,670 (9.3) 9,559 8,103 18.0 Other Income 92 125 (26.4) 85 8.0 388 411 (5.6) PBT 2,514 1,970 27.6 2,755 (8.8) 9,947 8,514 16.8 Exceptional 341 - na (117) na (117) - PBT after exceptional 2,855 1,970 44.9 2,639 8.2 9,830 8,514 15.5 Tax 960 606 58.4 751 27.8 3,097 2,740 13.0 RPAT 1,895 1,364 39.0 1,888 0.4 6,734 5,774 16.6 APAT 1,656 1,364 21.4 1,791 (7.5) 6,637 5,774 14.9 EPS (adjusted) 6.1 5.0 21.4 6.6 (7.5) 24.4 21.2 14.9 Source: Company, HDFC sec Inst Research
Margin Analysis
Particulars 1QFY19 1QFY18 YoY (bps) 4QFY18 QoQ
(bps) FY18 FY17 YoY (bps)
Material Expenses % Net Sales 34.1 36.6 (255) 34.3 (26) 35.6 37.1 (150) Employee Expenses % Net Sales 7.2 7.4 (24) 6.9 25 7.3 7.2 6 ASP Expenses % Net Sales 13.8 14.7 (87) 13.1 63 12.6 12.9 (27) Other Operating Expenses % Net Sales 17.9 18.6 (70) 17.4 51 18.0 19.1 (116) EBITDA Margin (%) 27.0 22.7 436 28.2 (113) 26.6 23.7 286 Tax Rate (%) 33.6 30.8 285 28.5 516 31.5 32.2 (68) APAT Margin (%) 18.2 13.9 426 17.3 91 16.1 14.5 158 Source: Company, HDFC sec Inst Research
Net revenue and volume growth of 6.6% and 4% was below our expectation. Competitive pressure from Dabur and Patanjali remained high Recent price cut of 15-16% for Swarna Vedshakti is to boost volume in natural segment Management expects recovery in the oral care market and expect market to grow by single digit (~6%) volume during FY19 Not encouraged by flat advertisement spend particularly when market share is falling and new launches needs extra efforts EBITDA margin expansion was driven by soft commodity inflation, favourable base and cost control initiatives
COLGATE-PALMOLIVE : RESULTS REVIEW 1QFY19
Page | 3
Net Revenue Volume Growth
Source: Company, HDFC sec Inst Research Note: 1QFY16-4QFY16 growth is based on old AS
Source: Company, HDFC sec Inst Research
Gross Margin Change EBITDA Margin Change
Source: Company, HDFC sec Inst Research Note: 1QFY16-4QFY16 change is based on old AS
Source: Company, HDFC sec Inst Research Note: 1QFY16-4QFY16 change is based on old AS
Volume growth challenges have persisted for the past several quarters driven by slower category growth and market share losses Soft commodity inflation leading to gross margin expansion Favourable base and cost control initiatives continue to expand EBITDA margin
(15.0)
(10.0)
(5.0)
-
5.0
10.0
15.0
20.0
25.0
-
3,000
6,000
9,000
12,000
1QFY
162Q
FY16
3QFY
164Q
FY16
1QFY
172Q
FY17
3QFY
174Q
FY17
1QFY
182Q
FY18
3QFY
184Q
FY18
1QFY
19
Net Sales YoY Growth - RHS
(Rs mn) (%)
3.0 3.0 1.0
6.0 6.0 4.0
(12.0)
(3.0)(5.0)
(0.9)
12.0
4.0 4.0
(15.0)
(10.0)
(5.0)
-
5.0
10.0
15.0
1QFY
16
2QFY
16
3QFY
16
4QFY
16
1 QFY
17
2QFY
17
3QFY
17
4QFY
17
1QFY
18
2QFY
18
3QFY
18
4QFY
18
1QFY
19
(%)
86
137 120
34
139
91 76
142 108
41
130
302
255
-
110
220
330
1QFY
16
2QFY
16
3QFY
16
4QFY
16
1QFY
17
2QFY
17
3QFY
17
4QFY
17
1QFY
18
2QFY
18
3QFY
18
4QFY
18
1QFY
19
(bps)
(26)
591
326
(211)(105)
(35) (47) (21)
183 171
286
462 436
(300)
(50)
200
450
700
1QFY
16
2QFY
16
3QFY
16
4QFY
16
1QFY
17
2QFY
17
3QFY
17
4QFY
17
1QFY
18
2QFY
18
3QFY
18
4QFY
18
1QFY
19
(bps)
COLGATE-PALMOLIVE : RESULTS REVIEW 1QFY19
Page | 4
Employee Expense Advertising Expense
Source: Company, HDFC sec Inst Research Note: 1QFY16-4QFY16 growth is based on old AS
Source: Company, HDFC sec Inst Research Note: 1QFY16-4QFY16 growth is based on old AS
Gross Margin EBITDA Margin
Source: Company, HDFC sec Inst Research Source: Company, HDFC sec Inst Research
We expect advertising spend would increase in the coming quarters. Colgate will spend more aggressively to support new launches
12
(16)
9 13
16
26
(1)
2
(2)
13 15
(1)
3
4.0
5.0
6.0
7.0
8.0
(25)
(10)
5
20
35
1QFY
16
2QFY
16
3QFY
16
4QFY
16
1QFY
17
2QFY
17
3QFY
17
4QFY
17
1 QFY
18
2QFY
18
3QFY
18
4QFY
18
1QFY
19
Employee Gr. (%) Employee (% of sales) - RHS(%)
11
(17)(11)
28 24 28
(21)
24
(8) (7)
44
(0)
0
-
5
10
15
20
25
(30)
-
30
60
1QFY
16
2QFY
16
3QFY
16
4QFY
16
1QFY
17
2QFY
17
3QFY
17
4QFY
17
1QFY
18
2QFY
18
3QFY
18
4QFY
18
1QFY
19
Advertising Gr. (%) Advertising (% of sales) - RHS(%)
60.9
62.1 63.1
61.2 62.3
63.0 63.9
62.6 63.4 63.4
65.2 65.7
65.9
57.0
59.0
61.0
63.0
65.0
67.0
1QFY
16
2QFY
16
3QFY
16
4QFY
16
1QFY
17
2QFY
17
3QFY
17
4QFY
17
1QFY
18
2QFY
18
3QFY
18
4QFY
18
1QFY
19
(%)
21.9
26.4 24.9
23.8
20.9
26.0 24.5
23.5 22.7
27.7 27.3 28.2 27.0
10.0
15.0
20.0
25.0
30.0
1QFY
16
2QFY
16
3QFY
16
4QFY
16
1QFY
17
2QFY
17
3QFY
17
4QFY
17
1QFY
18
2QFY
18
3QFY
18
4QFY
18
1QFY
19
(%)
COLGATE-PALMOLIVE : RESULTS REVIEW 1QFY19
Page | 5
Colgate’s Toothpaste Market Share Colgate’s Toothbrush Market Share
Source: Company, HDFC sec Inst Research Source: Company, HDFC sec Inst Research
Market share declines for Colgate in toothpaste have come from its premium segment (Colgate Sensitive and Colgate Total). The premium segment revenue contribution now is at ~4% vs. ~8% earlier Colgate continued to face intense competition in the naturals segment (25% mix for industry) which is dominated by Dabur and Patanjali (80% combined share)
57.8
57.9
57.6
57.3
55.3
55.9
55.7
55.4
55.1
54.3
54.0
53.7
53.4
52.4
49.0 50.0 51.0 52.0 53.0 54.0 55.0 56.0 57.0 58.0 59.0
4QFY
15
1QFY
16
2QFY
16
3QFY
16
4QFY
16
1QFY
17
2QFY
17
3QFY
17
4QFY
17
1QFY
18
2QFY
18
3QFY
18
4QFY
18
1QFY
19
(%)
42.7
43.3
43.8
45.8
46.8
46.6
47.0
47.4
45.0
45
.5
45.1
44.8
44.6
40.0
41.0
42.0
43.0
44.0
45.0
46.0
47.0
48.0
1QFY
16
2QFY
16
3QFY
16
4QFY
16
1QFY
17
2QFY
17
3QFY
17
4QFY
17
1QFY
18
2QFY
18
3QFY
18
4QFY
18
1QFY
19
(%)
COLGATE-PALMOLIVE : RESULTS REVIEW 1QFY19
Page | 6
Toothpaste Market Performance (Quarterly) Toothpaste Market Performance (Yearly)
Source: Company, HDFC sec Inst Research Source: Company, HDFC sec Inst Research Toothpaste Market Share
Source: Company, HDFC sec Inst Research
Toothpaste volume market growth has also slowed down~6% during the last 3 quarters Higher competitive intensity from Dabur and Patanjali has been impacting Colgate’s market share
-5%
0%
5%
10%
15%
20%
25%
1QCY
15
2QCY
15
3QCY
15
4QCY
15
1QCY
16
2QCY
16
3QCY
16
4QCY
16
1QCY
17
2QCY
17
3QCY
17
4QCY
17
1QCY
18
Volume Growth Price Growth
0.1% 2.1%
7.4%6.1%
5.9%
6.5%
0.0%
4.0%
8.0%
12.0%
16.0%
CY15
CY16
CY17
Volume Growth Price Growth
48.8 48.452.2 53.3 52.7 54.5 56.1 57.0 57.4 55.6 53.7
25.1 24.6 22.8 22.6 23.3 23.5 22.8 21.3 19.6 19.1 17.6
11.9 12.2 12.9 13.7 14.8 14.0 13.4 13.4 13.9 15.3 15.5
0.0 0.1 0.4 0.6 1.3 2.86.7
0.0
10.0
20.0
30.0
40.0
50.0
60.0
CY07 CY08 CY09 CY10 CY11 CY12 CY13 CY14 CY15 CY16 CY17
Colgate Competitor 1 Competitor 2 Competitor 3(%)
COLGATE-PALMOLIVE : RESULTS REVIEW 1QFY19
Page | 7
Toothbrush Market Performance (Quarterly) Toothbrush Market Performance (Yearly)
Source: Company, HDFC sec Inst Research Source: Company, HDFC sec Inst Research Toothbrush Market Share
Source: Company, HDFC sec Inst Research
Toothbrush volume market growth has been steady at ~10% while price growth has declined to 2% in last 3 quarters vs. 8-9% average during FY16-FY17 Higher competitive intensity from P&G (Oral-B) and unorganized players in toothbrush led to 260bps decline in vol. market share to 44.8%
-16.0%
-8.0%
0.0%
8.0%
16.0%
24.0%
32.0%
1QCY
15
2QCY
15
3QCY
15
4QCY
15
1QCY
16
2QCY
16
3QCY
16
4QCY
16
1QCY
17
2QCY
17
3QCY
17
4QCY
17
1QCY
18
Volume Growth Price Growth
9.3%
-4.1%
12.0%
10.3%
11.0%
3.1%
-7.0%
1.0%
9.0%
17.0%
25.0%
CY15
CY16
CY17
Volume Growth Price Growth
33.438.4 38.0 35.9
39.842.3 42.8 44.4
47.3 45.1
11.4 11.914.8
17.8 18.8 18.4 18.2 17.414.6 14.2
5.9 6.4 7.2 7.2 6.7 7.5 7.9 9.3 10.7 11.00.0
10.0
20.0
30.0
40.0
50.0
60.0
CY08 CY09 CY10 CY11 CY12 CY13 CY14 CY15 CY16 CY17
Colgate Competitor 1 Competitor 2(%)
COLGATE-PALMOLIVE : RESULTS REVIEW 1QFY19
Page | 8
Per Capita Consumption
Source: Company, HDFC sec Inst Research
Assumptions
FY17 FY18 FY19E FY20E FY21E Toothpaste revenue growth 2.7 5.8 8.3 11.3 11.3 Toothpaste volume growth (2.0) 2.5 5.1 7.5 7.5 GM (%) 62.9 64.4 65.5 66.3 66.8 Employee (% of sales) 7.2 7.3 7.2 7.0 6.8 ASP (% of sales) 12.9 12.6 13.0 13.0 13.0 Distribution (% of sales) 3.6 3.1 3.1 3.1 3.1 Royalty (% of sales) 5.2 4.9 4.9 4.9 4.9 Other expenses (% of sales) 10.3 9.9 9.7 9.6 9.6 EBITDA Margin (%) 23.7 26.6 27.6 28.7 29.4 Tax Rate (%) 32.2 31.5 32.0 32.0 32.0 Source: Company, HDFC sec Inst Research
603
458
312
212158
0
100
200
300
400
500
600
700
Brazil USA Philipines China India
With stiff competition, we expect Colgate to continue to spend abundantly on marketing (13%). We foresee low-margin expansion of ~300bps over FY18-21E vs. ~600bps in the past three years
COLGATE-PALMOLIVE : RESULTS REVIEW 1QFY19
Page | 9
Estimate change
NEW OLD Change (%)
FY19E FY20E FY21E FY19E FY20E FY21E FY19E FY20E FY21E Net Sales 45,628 50,806 56,508 46,703 52,693 58,606 -2% -4% -4% EBITDA 12,588 14,580 16,617 12,761 14,833 16,906 -1% -2% -2% PAT 7,825 8,931 10,285 7,922 9,353 10,771 -1% -5% -5% EPS 28.7 32.8 37.8 29.1 34.4 39.6 -1% -5% -5% Peer Set Comparison
Company MCap (Rs bn)
CMP (Rs) Reco. TP
(Rs) EPS (Rs) P/E (x) EV/EBITDA (x) Core RoCE (%)
FY19E FY20E FY21E FY19E FY20E FY21E FY19E FY20E FY21E FY19E FY20E FY21E HUL 3,605 1,669 NEU 1,709 29.4 35.5 42.7 56.7 47.0 39.1 39.4 33.1 27.9 71.4 73.8 74.4 ITC 3,486 287 BUY 367 10.1 11.1 12.3 28.5 25.9 23.4 17.9 15.9 14.2 37.9 40.1 43.0 GCPL 850 1,248 NR 1,143 26.8 30.8 36.7 46.5 40.5 34.0 35.3 30.2 25.4 20.3 22.9 26.9 Britannia 774 6,450 NEU 6,307 103.2 132.4 158.6 62.5 48.7 40.7 41.9 33.2 27.8 45.7 52.4 56.0 Dabur 657 373 BUY 423 9.4 11.3 13.7 39.7 32.9 27.2 32.8 27.6 23.5 56.8 67.5 77.3 Marico 471 365 BUY 379 8.1 10.4 12.1 45.1 35.1 30.2 32.9 25.9 22.4 45.6 55.7 61.4 Colgate 295 1,085 NEU 1,185 28.7 32.8 37.8 37.7 33.0 28.7 23.1 19.7 17.0 69.6 81.9 96.1 Emami 253 555 BUY 627 14.0 16.6 19.9 39.6 33.4 27.9 29.0 24.6 20.7 27.6 34.0 43.4 Jub. Food 184 1,396 BUY 1,562 25.8 31.8 39.2 54.0 43.9 35.6 28.8 23.9 19.9 56.6 71.9 89.2 Source: HDFC sec Inst Research
COLGATE-PALMOLIVE : RESULTS REVIEW 1QFY19
Page | 10
Income Statement (Rs mn) FY17 FY18 FY19E FY20E FY21E Net Revenues 39,818 41,880 45,628 50,806 56,508 Growth (%) 2.9 5.2 9.0 11.3 11.2 Material Expenses 14,763 14,901 15,724 17,540 19,171 Employee Expense 2,885 3,059 3,283 3,673 4,085 ASP Expense 5,117 5,268 5,932 6,605 7,346 Distribution Expense 1,424 1,315 1,414 1,575 1,752 Other Expenses 6,185 6,212 6,688 6,833 7,537 EBITDA 9,444 11,124 12,588 14,580 16,617 EBITDA Growth (%) 0.7 17.8 13.2 15.8 14.0 EBITDA Margin (%) 23.7 26.6 27.6 28.7 29.4 Depreciation 1,332 1,565 1,791 2,004 2,218 EBIT 8,112 9,559 10,796 12,576 14,400 Other Income (Inc. EO Items) 403 272 711 558 725 Interest - - - - - PBT 8,514 9,830 11,508 13,134 15,125 Total Tax 2,740 3,097 3,682 4,203 4,840 RPAT 5,774 6,734 7,825 8,931 10,285 Exceptional Gain/(loss) - (97) - - - Adjusted PAT 5,774 6,637 7,825 8,931 10,285 APAT Growth (%) (4.2) 14.9 17.9 14.1 15.2 Adjusted EPS (Rs) 21.2 24.4 28.7 32.8 37.8 EPS Growth (%) (4.2) 14.9 17.9 14.1 15.2
Source: Company, HDFC sec Inst Research
Balance Sheet (Rs mn) FY17 FY18 FY19E FY20E FY21E SOURCES OF FUNDS Share Capital - Equity 272 272 272 272 272 Reserves 12,466 14,974 14,937 18,218 21,516 Total Shareholders’ Funds 12,738 15,246 15,209 18,490 21,788 Long Term Debt - - - - - Short Term Debt - - - - - Total Debt - - - - - Net Deferred Taxes 275 355 355 355 355 Other Non-current Liabilities & Provns 268 209 209 209 209
TOTAL SOURCES OF FUNDS 13,281 15,811 15,774 19,054 22,353 APPLICATION OF FUNDS Net Block 11,081 11,460 11,669 11,664 11,446 CWIP 1,666 1,586 1,586 1,586 1,586 Other Non-current Assets 1,865 1,978 2,158 2,398 2,662 Total Non-current Assets 14,612 15,024 15,412 15,648 15,694 Inventories 2,926 2,267 2,471 2,750 3,057 Debtors 1,299 2,010 1,939 2,159 2,402 Other Current Assets 1,015 1,465 1,611 1,772 1,950 Cash & Equivalents 3,255 4,873 4,909 8,315 12,012 Total Current Assets 8,494 10,615 10,931 14,997 19,421 Creditors 5,975 6,145 6,601 7,238 7,970 Other Current Liabilities & Provns 3,851 3,683 3,968 4,353 4,792 Total Current Liabilities 9,826 9,828 10,569 11,590 12,762 Net Current Assets (1,332) 788 362 3,407 6,659 TOTAL APPLICATION OF FUNDS 13,281 15,811 15,774 19,054 22,353
Source: Company, HDFC sec Inst Research
COLGATE-PALMOLIVE : RESULTS REVIEW 1QFY19
Page | 11
Cash Flow Statement (Rs mn) FY17 FY18 FY19E FY20E FY21E Reported PBT 8,514 9,947 11,508 13,134 15,125 Non-operating & EO Items 28 81 - - - Interest Expenses (292) (290) - - - Depreciation 1,332 1,565 1,791 2,004 2,218 Working Capital Change 311 (889) 432 328 409 Tax Paid (3,014) (3,474) (3,682) (4,203) (4,840) OPERATING CASH FLOW ( a ) 6,880 6,939 10,048 11,263 12,911 Capex (3,213) (2,087) (2,000) (2,000) (2,000) Free Cash Flow (FCF) 3,667 4,852 8,048 9,263 10,911 Investments (506) (273) - - - Non-operating Income 297 287 (147) (203) (224) INVESTING CASH FLOW ( b ) (3,421) (2,073) (2,147) (2,203) (2,224) Debt Issuance/(Repaid) - - - - - FCFE 3,458 4,866 7,901 9,060 10,687 Share Capital Issuance - - - - - Dividend (3,271) (3,705) (7,862) (5,650) (6,986) Others (135) (92) (4) (4) (4) FINANCING CASH FLOW ( c ) (3,406) (3,798) (7,866) (5,654) (6,990) NET CASH FLOW (a+b+c) 53 1,068 36 3,406 3,697 EO Items, Others (4) (550) 0 (0) 0 Closing Cash & Equivalents 2,943 4,562 4,597 8,004 11,701
Source: Company, HDFC sec Inst Research
Key Ratios FY17 FY18 FY19E FY20E FY21E PROFITABILITY (%) GPM 62.9 64.4 65.5 65.5 66.1 EBITDA Margin 23.7 26.6 27.6 28.7 29.4 EBIT Margin 20.4 22.8 23.7 24.8 25.5 APAT Margin 14.5 15.8 17.2 17.6 18.2 RoE 50.1 47.4 51.4 53.0 51.1 RoIC (or Core RoCE) 64.5 64.4 69.6 81.9 96.1 RoCE 49.1 46.6 50.7 52.4 50.5 EFFICIENCY Tax Rate (%) 32.2 31.5 32.0 32.0 32.0 Fixed Asset Turnover (x) 2.2 2.1 2.1 2.1 2.2 Inventory (days) 26.8 19.8 19.8 19.8 19.7 Debtors (days) 11.9 17.5 15.5 15.5 15.5 Other Current Assets (days) 9.3 12.8 12.9 12.7 12.6 Payables (days) 54.8 53.6 52.8 52.0 51.5 Other Current Liab & Provns (days) 35.3 32.1 31.7 31.3 31.0 Cash Conversion Cycle (days) (42.0) (35.6) (36.4) (35.3) (34.6) Net D/E (x) (0.3) (0.3) (0.3) (0.4) (0.6) Interest Coverage (x) na na na na na PER SHARE DATA (Rs) EPS 21.2 24.4 28.7 32.8 37.8 CEPS 26.1 30.1 35.3 40.2 45.9 Dividend 10.0 24.0 17.2 21.3 24.6 Book Value 46.8 56.0 55.9 67.9 80.0 VALUATION P/E (x) 51.1 44.5 37.7 33.0 28.7 P/BV (x) 23.2 19.4 19.4 16.0 13.5 EV/EBITDA (x) 30.9 26.1 23.1 19.7 17.0 EV/Revenues (x) 7.3 6.9 6.4 5.6 5.0 OCF/EV (%) 2.4 2.4 3.5 3.9 4.6 FCF/EV (%) 1.2 1.7 2.7 3.2 3.8 FCFE/Mkt Cap (%) 1.2 1.6 2.7 3.1 3.6 Dividend Yield (%) 0.9 2.2 1.6 2.0 2.3
Source: Company, HDFC sec Inst Research
COLGATE-PALMOLIVE : RESULTS REVIEW 1QFY19
Page | 12
RECOMMENDATION HISTORY
Rating Definitions BUY : Where the stock is expected to deliver more than 10% returns over the next 12 month period NEUTRAL : Where the stock is expected to deliver (-)10% to 10% returns over the next 12 month period SELL : Where the stock is expected to deliver less than (-)10% returns over the next 12 month period
Date CMP Reco Target 4-Aug-17 1,083 NEU 1,062 10-Oct-17 1,090 NEU 1,112 13-Nov-17 1,063 NEU 1,110 27-Dec-17 1,082 NEU 1,118 12-Jan-18 1,125 NEU 1,139 6-Feb-18 1,121 NEU 1,163
12-Mar-18 1,038 BUY 1,204 11-Apr-18 1,091 BUY 1,204 21-May-18 1,208 NEU 1,203
9-Jul-18 1,183 NEU 1,219 27-Jul-18 1,085 NEU 1,185
800850900950
1,0001,0501,1001,1501,2001,2501,300
Jul-1
7
Aug-
17
Sep-
17
Oct
-17
Nov-
17
Dec-
17
Jan-
18
Feb-
18
Mar
-18
Apr-
18
May
-18
Jun-
18
Jul-1
8
Colgate TP
COLGATE-PALMOLIVE : RESULTS REVIEW 1QFY19
Page | 13
Disclosure: We, Naveen Trivedi, MBA & Siddhant Chhabria, PGDBM, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. HSL has no material adverse disciplinary history as on the date of publication of this report. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. Research Analyst or his/her relative or HDFC Securities Ltd. does not have any financial interest in the subject company. Also Research Analyst or his relative or HDFC Securities Ltd. or its Associate may have beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of the Research Report. Further Research Analyst or his relative or HDFC Securities Ltd. or its associate does not have any material conflict of interest. Any holding in stock –No HDFC Securities Limited (HSL) is a SEBI Registered Research Analyst having registration no. INH000002475. Disclaimer: This report has been prepared by HDFC Securities Ltd and is meant for sole use by the recipient and not for circulation. The information and opinions contained herein have been compiled or arrived at, based upon information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. This document is for information purposes only. Descriptions of any company or companies or their securities mentioned herein are not intended to be complete and this document is not, and should not be construed as an offer or solicitation of an offer, to buy or sell any securities or other financial instruments. This report is not directed to, or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity who is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject HSL or its affiliates to any registration or licensing requirement within such jurisdiction. If this report is inadvertently send or has reached any individual in such country, especially, USA, the same may be ignored and brought to the attention of the sender. This document may not be reproduced, distributed or published for any purposes without prior written approval of HSL. Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations, which could have an adverse effect on their value or price, or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies effectively assume currency risk. It should not be considered to be taken as an offer to sell or a solicitation to buy any security. HSL may from time to time solicit from, or perform broking, or other services for, any company mentioned in this mail and/or its attachments. HSL and its affiliated company(ies), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions. HSL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc. HSL and other group companies, its directors, associates, employees may have various positions in any of the stocks, securities and financial instruments dealt in the report, or may make sell or purchase or other deals in these securities from time to time or may deal in other securities of the companies / organizations described in this report. HSL or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months. HSL or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from t date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction in the normal course of business. HSL or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither HSL nor Research Analysts have any material conflict of interest at the time of publication of this report. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. HSL may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. Research entity has not been engaged in market making activity for the subject company. Research analyst has not served as an officer, director or employee of the subject company. We have not received any compensation/benefits from the subject company or third party in connection with the Research Report. HDFC securities Limited, I Think Techno Campus, Building - B, "Alpha", Office Floor 8, Near Kanjurmarg Station, Opp. Crompton Greaves, Kanjurmarg (East), Mumbai 400 042 Phone: (022) 3075 3400 Fax: (022) 2496 5066 Compliance Officer: Binkle R. Oza Email: [email protected] Phone: (022) 3045 3600 HDFC Securities Limited, SEBI Reg. No.: NSE-INB/F/E 231109431, BSE-INB/F 011109437, AMFI Reg. No. ARN: 13549, PFRDA Reg. No. POP: 04102015, IRDA Corporate Agent License No.: HDF 2806925/HDF C000222657, SEBI Research Analyst Reg. No.: INH000002475, CIN - U67120MH2000PLC152193 Mutual Funds Investments are subject to market risk. Please read the offer and scheme related documents carefully before investing.
COLGATE-PALMOLIVE : RESULTS REVIEW 1QFY19
Page | 14
HDFC securities Institutional Equities Unit No. 1602, 16th Floor, Tower A, Peninsula Business Park, Senapati Bapat Marg, Lower Parel,Mumbai - 400 013 Board : +91-22-6171 7330www.hdfcsec.com